Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus ANDROID 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus ANDROID 5.
ANDROID 10 vs ANDROID 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Category C
Category C
Androgen
Androgen